Last reviewed · How we verify
NCT05155657
Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells
Phase 1 trial testing Conventional therapy plus low dose UCMSCs treatment in Alcoholic Cirrhosis in 36 participants. Status unknown.
25 December 2024
Quick facts
| Lead sponsor | Yantai Yuhuangding Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 13 June 2022 |
| Primary completion | 25 December 2024 |
| Estimated completion | 25 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Conventional therapy plus low dose UCMSCs treatment — full drug profile →
- Conventional therapy plus medium dose UCMSCs treatment — full drug profile →
- Conventional therapy plus high dose UCMSCs treatment — full drug profile →
Conditions studied
- Alcoholic Cirrhosis — all drugs for Alcoholic Cirrhosis →
Sponsor
Yantai Yuhuangding Hospital
Who can join
Adults 18 to 60, any sex, with Alcoholic Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated alcoholic cirrhosis (DAC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.
Yang X, Li Q, Liu W, Zong C, et al · · 2023 · cited 84× · PMID 36823236 · DOI 10.1038/s41423-023-00983-5 -
Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.
Qin L, Liu N, Bao CL, Yang DZ, et al · · 2023 · cited 74× · PMID 35896695 · DOI 10.1038/s41401-022-00952-0 -
Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms.
Hazrati A, Malekpour K, Soudi S, Hashemi SM. · · 2022 · cited 38× · PMID 35464407 · DOI 10.3389/fimmu.2022.865888 -
The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma.
Lu Y, Lin B, Li M. · · 2024 · cited 22× · PMID 38660138 · DOI 10.3389/fonc.2024.1363695 -
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M, Bayati P, Mojtabavi N. · · 2024 · cited 18× · PMID 38886859 · DOI 10.1186/s13287-024-03782-5 -
The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases.
Nikokiraki C, Psaraki A, Roubelakis MG. · · 2022 · cited 17× · PMID 35563716 · DOI 10.3390/cells11091410 -
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Huang WC, Li YC, Chen PX, Ma KS, et al · · 2025 · cited 14× · PMID 39762946 · DOI 10.1186/s13287-024-04127-y -
From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy.
Bozorgi V, Babaahmadi M, Salehi M, Vafaeimanesh J, et al · · 2025 · cited 4× · PMID 40764597 · DOI 10.1186/s13287-025-04535-8
Verify or expand the search:
- PubMed search for NCT05155657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcoholic Cirrhosis
Currently open trials in the same condition.
- NCT06866496 — Optimized Remission in Alcohol-related Liver Cirrhosis · NA · recruiting
- NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
- NCT04689152 — Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis · Phase 3 · recruiting
- NCT04250259 — SAMe Trial for Patients With Alcoholic Cirrhosis · Phase 2 · recruiting
Other Yantai Yuhuangding Hospital trials
Trials by the same sponsor.
- NCT07054242 — A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvan · Phase 2 · not yet recruiting
- NCT06499818 — CPVI Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF f · NA · not yet recruiting
- NCT05800756 — Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer · Phase 2 · unknown
- NCT05151133 — Clinical Study of Allergic Rhinitis Therapy by Stem Cells · Phase 1 · unknown
- NCT06388005 — The Application of Emotion Release Technology in Anxiety Patients Before Daytime Thyroid Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05155657 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yantai Yuhuangding Hospital
- Last refreshed: 28 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05155657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing